In vitro and in vivo anticancer activity of mebendazole in colon cancer: a promising drug repositioning. (2024)

Peer-Reviewed Study · Amin Aliabadi; Mohammad Reza Haghshenas; Razie Kiani et al. · April 2024

Amin Aliabadi et al., 2024-04: Iranian study of mebendazole against CT26 colon cancer in BALB/c mice, reporting reduced tumour volume and weight and improved survival alongside in vitro cytotoxicity.

The mice were treated with 0.05 of LD50, intraperitoneal, every other day for 35 days.

Amin Aliabadi et al., 2024-04: Iranian study of mebendazole against CT26 colon cancer in BALB/c mice, reporting reduced tumour volume and weight and improved survival alongside in vitro cytotoxicity. Study type: mouse CT26 subcutaneous colon cancer model plus HT-29 and MCF-10 cell lines. N: not stated in the abstract. Country: Iran (Shiraz University of Medical Sciences). Dose: 0.05 of LD50, intraperitoneal, every other day for 35 days. Funder: Shiraz University of Medical Sciences (21962) and Shiraz Institute for Cancer Research (ICR-100-500). Declared conflicts: no COI statement in the record. Comparator: doxorubicin as positive control in vitro, and untreated tumour-bearing mice in vivo. Study type: animal.